Recep Dursun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Recep Dursun has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Selami Aykut Temiz
Department of Dermatology, Necmettin Erbakan University Medical Faculty, Konya, Turkey
25 shared publications - Arzu Ataseven
Department of Dermatology Necmettin Erbakan University Meram Medical Faculty Konya Turkey
16 shared publications - İlkay Ozer
Department of Dermatology and Venereology, Faculty of Medicine, Necmettin Erbakan University, Konya 42060, Türkiye
13 shared publications - Munise Daye
Department of Dermatology and Venereology Necmettin Erbakan University Konya Turkey
10 shared publications - Begüm Işık
Department of Dermatology Necmettin Erbakan University Meram Medical Faculty Konya Turkey
5 shared publications - Koray Durmaz
Clinic of Dermatology Bozuyuk State Hospital Bilecik Turkey
5 shared publications
Latest Publications
- 14 September 2026
- Published by Necmettin Erbakan University in Selcuk Tip Dergisi
Investigation of The Anti-İnflammatory Effect of İsotretinoin in Patients with Acne Vulgaris, A New İndicator: Systemic İnflammation Aggregate İndex
Amaç: Akne vulgaris, kronik inflamatuar bir hastalıktır. Bir A vitamini türevi olan izotretinoin, akne tedavisinde yaygın olarak kullanılmaktadır. İzotretinoinin sistemik inflamasyon üzerindeki etkileri literatürde çelişkili sonuçlara sahiptir. Nötrofil-lenfosit oranı (NLR), sistemik inflamatuar yanıt indeksi (SIRI), sistemik immüninflamatuar indeksi (SII) ve sistemik inflamasyonun toplam indeksi (AISI), tam kan sayımından elde edilen, ucuz ve kolay hesaplanabilen biyobelirteçlerdir ve sistemik ve dermatolojik inflamatuar hastalıklarda inflamasyonun varlığını değerlendirmek için kullanılmaktadır. Bu çalışmanın amacı, akne vulgaris hastalarında izotretinoin tedavisi sırasında bu sistemik inflamatuar belirteçlerdeki değişiklikleri değerlendirmektir. Gereç ve Yöntemler: Çalışmaya, akne vulgaris tedavisi için izotretinoin tedavisi gören 183 hasta dahil edildi. Tam kan sayımları 0, 3 ve 6. aylarda retrospektif olarak kaydedildi ve NLR, SII, SIRI ve AISI değerleri analiz edildi. Bulgular: Mutlak nötrofil sayısı, başlangıç değerine kıyasla 6. ayda azaldı (p=0,032) ve lenfosit sayısı 3. ve 6. aylarda arttı (sırasıyla p=0,003 ve p=0,043). Trombosit sayısı, 3. ayın sonunda arttı ve 6. ayın sonunda başlangıç değerine kıyasla azaldı (sırasıyla p=0,002 ve p=0,012). NLR, SIRI, SII ve AISI değerleri tedavi sırasında azalmaya devam etmiş ve 6. ayın sonunda önemli bir azalma gözlemlenmiştir (sırasıyla p=0,001, p=0,006, p=0,016, p=0,029). Sonuç: Akne vulgaris hastalarında sistemik izotretinoin tedavisi, NLR, SIRI, SII ve AISI'da önemli azalmalarla ilişkilidir. Bu bulgular, izotretinoinin sistemik antiinflamatuar etkisinin varlığını desteklemekte ve sistemik inflamasyon üzerindeki etkisine ilişkin süregelen tartışmaya katkıda bulunmaktadır.
- 14 September 2026
- Published by Necmettin Erbakan University in Selcuk Tip Dergisi
Investigation of The Anti-İnflammatory Effect of İsotretinoin in Patients with Acne Vulgaris, A New İndicator: Systemic İnflammation Aggregate İndex
Amaç: Akne vulgaris, kronik inflamatuar bir hastalıktır. Bir A vitamini türevi olan izotretinoin, akne tedavisinde yaygın olarak kullanılmaktadır. İzotretinoinin sistemik inflamasyon üzerindeki etkileri literatürde çelişkili sonuçlara sahiptir. Nötrofil-lenfosit oranı (NLR), sistemik inflamatuar yanıt indeksi (SIRI), sistemik immüninflamatuar indeksi (SII) ve sistemik inflamasyonun toplam indeksi (AISI), tam kan sayımından elde edilen, ucuz ve kolay hesaplanabilen biyobelirteçlerdir ve sistemik ve dermatolojik inflamatuar hastalıklarda inflamasyonun varlığını değerlendirmek için kullanılmaktadır. Bu çalışmanın amacı, akne vulgaris hastalarında izotretinoin tedavisi sırasında bu sistemik inflamatuar belirteçlerdeki değişiklikleri değerlendirmektir. Gereç ve Yöntemler: Çalışmaya, akne vulgaris tedavisi için izotretinoin tedavisi gören 183 hasta dahil edildi. Tam kan sayımları 0, 3 ve 6. aylarda retrospektif olarak kaydedildi ve NLR, SII, SIRI ve AISI değerleri analiz edildi. Bulgular: Mutlak nötrofil sayısı, başlangıç değerine kıyasla 6. ayda azaldı (p=0,032) ve lenfosit sayısı 3. ve 6. aylarda arttı (sırasıyla p=0,003 ve p=0,043). Trombosit sayısı, 3. ayın sonunda arttı ve 6. ayın sonunda başlangıç değerine kıyasla azaldı (sırasıyla p=0,002 ve p=0,012). NLR, SIRI, SII ve AISI değerleri tedavi sırasında azalmaya devam etmiş ve 6. ayın sonunda önemli bir azalma gözlemlenmiştir (sırasıyla p=0,001, p=0,006, p=0,016, p=0,029). Sonuç: Akne vulgaris hastalarında sistemik izotretinoin tedavisi, NLR, SIRI, SII ve AISI'da önemli azalmalarla ilişkilidir. Bu bulgular, izotretinoinin sistemik antiinflamatuar etkisinin varlığını desteklemekte ve sistemik inflamasyon üzerindeki etkisine ilişkin süregelen tartışmaya katkıda bulunmaktadır.
- 20 August 2026
- Published by Taylor & Francis in Cutaneous and Ocular Toxicology
- p. 1-7
Evaluation of hematological parameters and treatment response in patients with alopecia areata treated with diphenylcyclopropenone: an exploratory retrospective study
Alopecia areata (AA) is a chronic inflammatory disease characterized by non-scarring hair loss that can affect hair follicles on the scalp and body, and may also involve the nails. It affects appro...
- 20 August 2026
- Published by Taylor & Francis in Cutaneous and Ocular Toxicology
- p. 1-7
Evaluation of hematological parameters and treatment response in patients with alopecia areata treated with diphenylcyclopropenone: an exploratory retrospective study
Alopecia areata (AA) is a chronic inflammatory disease characterized by non-scarring hair loss that can affect hair follicles on the scalp and body, and may also involve the nails. It affects appro...
- 11 July 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 243
Assessment of increased risk of atherothrombotic cardiovascular disease in patients with lichen planus: a case-control study
- 11 July 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 243
Assessment of increased risk of atherothrombotic cardiovascular disease in patients with lichen planus: a case-control study
- 30 March 2026
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 53 (7) , 633-639
IL ‐17, IL ‐23, and IL ‐36α Expression in Palmoplantar Psoriasis, Palmoplantar Eczema, and Plaque Psoriasis: Implications on Diagnosis and Treatment Selection
Background: Palmoplantar psoriasis exhibits greater treatment resistance compared to other psoriatic plaques and presents clinical and histopathological overlap with palmoplantar eczema. This study aimed to investigate treatment resistance mechanisms in palmoplantar psoriasis and assess the contribution of IL‐17, IL‐23, and IL‐36α to the differential diagnosis of palmoplantar psoriasis and eczema. Immunohistochemical levels of these cytokines were measured in paired acral and non‐acral psoriatic samples. Methods: We retrospectively included 73 patients: 25 with only palmoplantar psoriasis, 25 with palmoplantar eczema, and 23 with both conditions and concurrent plaque psoriasis. Clinical and histopathological diagnoses were confirmed. Immunohistochemical analyses were conducted using preparations stained for IL‐17, IL‐23, and IL‐36α. Results: In psoriasis cases, immunohistochemical examination of biopsies from both body and palmoplantar regions showed lower IL‐17 and IL‐36α expression in acral regions compared to non‐acral regions. In palmoplantar eczema patients, IL‐17 and IL‐23 expression was higher than in palmoplantar psoriasis patients; however, IL‐36α expression was similar in both conditions. Conclusions: The diminished expression of IL‐17 and IL‐36α in palmoplantar psoriasis compared to other body sites may contribute to variable responses to targeted treatments. These findings suggest the potential for developing distinct biological treatments for these regions.
- 30 March 2026
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 53 (7) , 633-639
IL ‐17, IL ‐23, and IL ‐36α Expression in Palmoplantar Psoriasis, Palmoplantar Eczema, and Plaque Psoriasis: Implications on Diagnosis and Treatment Selection
Background: Palmoplantar psoriasis exhibits greater treatment resistance compared to other psoriatic plaques and presents clinical and histopathological overlap with palmoplantar eczema. This study aimed to investigate treatment resistance mechanisms in palmoplantar psoriasis and assess the contribution of IL‐17, IL‐23, and IL‐36α to the differential diagnosis of palmoplantar psoriasis and eczema. Immunohistochemical levels of these cytokines were measured in paired acral and non‐acral psoriatic samples. Methods: We retrospectively included 73 patients: 25 with only palmoplantar psoriasis, 25 with palmoplantar eczema, and 23 with both conditions and concurrent plaque psoriasis. Clinical and histopathological diagnoses were confirmed. Immunohistochemical analyses were conducted using preparations stained for IL‐17, IL‐23, and IL‐36α. Results: In psoriasis cases, immunohistochemical examination of biopsies from both body and palmoplantar regions showed lower IL‐17 and IL‐36α expression in acral regions compared to non‐acral regions. In palmoplantar eczema patients, IL‐17 and IL‐23 expression was higher than in palmoplantar psoriasis patients; however, IL‐36α expression was similar in both conditions. Conclusions: The diminished expression of IL‐17 and IL‐36α in palmoplantar psoriasis compared to other body sites may contribute to variable responses to targeted treatments. These findings suggest the potential for developing distinct biological treatments for these regions.
- 17 February 2026
- Published by Academician Publishing
- p. 267-280
Cosmetic Procedures (Cosmetic Applications in Geriatric Population)
Aging is characterized by cosmetic changes in the skin, and while these changes may not directly threaten physical health, their psychological effects should not be overlooked. The impact on self-perception, self-esteem, and quality of life is particularly significant. With the increase in the elderly population, dissatisfaction with skin changes due to aging will attract more attention from physicians, increasing the need to address this issue. There are various methods available to delay skin aging. Dermatologists are the most qualified specialists to recommend these methods for aging individuals. Doctors, particularly dermatologists, geriatricians, gerontologists, and plastic surgeons, should remember that when advising elderly individuals on cosmetic and personal care products, these products are an important part of their lives. In this section, we aim to explore the cosmetic options applicable to the geriatric patient population and address the changes in the skin associated with aging, as well as the differences compared to other age groups.
- 17 February 2026
- Published by Academician Publishing
- p. 267-280
Cosmetic Procedures (Cosmetic Applications in Geriatric Population)
Aging is characterized by cosmetic changes in the skin, and while these changes may not directly threaten physical health, their psychological effects should not be overlooked. The impact on self-perception, self-esteem, and quality of life is particularly significant. With the increase in the elderly population, dissatisfaction with skin changes due to aging will attract more attention from physicians, increasing the need to address this issue. There are various methods available to delay skin aging. Dermatologists are the most qualified specialists to recommend these methods for aging individuals. Doctors, particularly dermatologists, geriatricians, gerontologists, and plastic surgeons, should remember that when advising elderly individuals on cosmetic and personal care products, these products are an important part of their lives. In this section, we aim to explore the cosmetic options applicable to the geriatric patient population and address the changes in the skin associated with aging, as well as the differences compared to other age groups.
- 28 January 2026
- Published by Taylor & Francis in Cutaneous and Ocular Toxicology
- Vol. 45 (2) , 172-179
Assessment of cardiovascular risk in lichen planus cases with epicardial adipose tissue thickness and plasma atherogenic index
Lichen planus (LP) is an idiopathic, chronic, inflammatory dermatosis that can affect the skin, its appendages, and mucous membranes. Chronic inflammatory dermatoses may contribute to metabolic complications and increase cardiovascular risk. This study aimed to evaluate cardiovascular risk in patients with LP by assessing the Plasma Atherogenic Index (PAI) and Epicardial Adipose Tissue (EAT) thickness. A case-control study was conducted, including a total of 150 individuals, comprising 75 patients with LP and 75 age-, sex-, and body mass index (BMI)-matched controls. Lipid profiles were analyzed, and the PAI (log10[triglycerides (TG)/high-density lipoprotein cholesterol (HDL-C)]) was calculated. EAT thickness was measured using transthoracic echocardiography. In the study, 40% of participants were male and 60% female in both groups. Dyslipidemia was identified in 66.7% of the case group and 50.7% of the control group, with the presence of dyslipidemia being significantly higher in the LP group (p < 0.05). Among the cases, 82.7% were in the high, 6.7% in the moderate, and 10.7% in the low cardiovascular risk category. PAI values and mean EAT thickness were significantly higher in the LP group than in controls (both p < 0.05). The findings support an association between LP and markers of increased subclinical cardiovascular risk rather than established cardiovascular disease. Early recognition and regular screening for cardiometabolic risk factors in dermatology practice, as well as multidisciplinary collaboration with cardiologists, may help prevent long-term cardiovascular complications in patients with LP.
- 28 January 2026
- Published by Taylor & Francis in Cutaneous and Ocular Toxicology
- Vol. 45 (2) , 172-179
Assessment of cardiovascular risk in lichen planus cases with epicardial adipose tissue thickness and plasma atherogenic index
Lichen planus (LP) is an idiopathic, chronic, inflammatory dermatosis that can affect the skin, its appendages, and mucous membranes. Chronic inflammatory dermatoses may contribute to metabolic complications and increase cardiovascular risk. This study aimed to evaluate cardiovascular risk in patients with LP by assessing the Plasma Atherogenic Index (PAI) and Epicardial Adipose Tissue (EAT) thickness. A case-control study was conducted, including a total of 150 individuals, comprising 75 patients with LP and 75 age-, sex-, and body mass index (BMI)-matched controls. Lipid profiles were analyzed, and the PAI (log10[triglycerides (TG)/high-density lipoprotein cholesterol (HDL-C)]) was calculated. EAT thickness was measured using transthoracic echocardiography. In the study, 40% of participants were male and 60% female in both groups. Dyslipidemia was identified in 66.7% of the case group and 50.7% of the control group, with the presence of dyslipidemia being significantly higher in the LP group (p < 0.05). Among the cases, 82.7% were in the high, 6.7% in the moderate, and 10.7% in the low cardiovascular risk category. PAI values and mean EAT thickness were significantly higher in the LP group than in controls (both p < 0.05). The findings support an association between LP and markers of increased subclinical cardiovascular risk rather than established cardiovascular disease. Early recognition and regular screening for cardiometabolic risk factors in dermatology practice, as well as multidisciplinary collaboration with cardiologists, may help prevent long-term cardiovascular complications in patients with LP.
- 2 October 2025
- Published by Taylor & Francis in Cutaneous and Ocular Toxicology
- Vol. 44 (4) , 544-550
Effect of interleukin 23 inhibitors (risankizumab and guselkumab) on cardiovascular and cerebrovascular risk in psoriasis patients
Psoriasis is a chronic systemic inflammatory disease mediated by the immune system. Interleukin-23 (IL-23) plays a key role in its pathogenesis by amplifying inflammation, triggering atherogenic dyslipidemia and insulin resistance, and thereby increasing cardiovascular and cerebrovascular risk. This study aimed to evaluate the effect of the IL-23 inhibitors risankizumab and guselkumab, used in psoriasis treatment, on cardiovascular and cerebrovascular risk through the plasma atherogenic index (PAI) and triglyceride-glucose (TyG) index. This retrospective study included 110 patients diagnosed with psoriasis and treated with risankizumab (n = 61) or guselkumab (n = 49). Psoriasis Area and Severity Index (PASI) scores, triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C) levels and fasting blood glucose (FBG) values at baseline and at 6 months of treatment were obtained from patient records. The plasma atherogenic index (PAI) was calculated as log₁。(TG/HDL-C), and the triglyceride-glucose (TyG) index as log₁。(TG × FBG / 2). In both IL-23 inhibitor groups included in the study, PASI scores, PAI, and TyG index values showed a significant decrease from baseline at the 6th month of treatment (p < 0.05). However, there was no significant difference in the reduction of index levels between the groups (p > 0.05). IL-23 inhibitors can reduce atherogenic dyslipidemia and insulin resistance alongside dermatological improvement in the treatment of psoriasis. This suggests a potential role for these agents in reducing the risk of cardiovascular and cerebrovascular disease. However, large-scale, long-term studies are needed to confirm these beneficial effects.
- 2 October 2025
- Published by Taylor & Francis in Cutaneous and Ocular Toxicology
- Vol. 44 (4) , 544-550
Effect of interleukin 23 inhibitors (risankizumab and guselkumab) on cardiovascular and cerebrovascular risk in psoriasis patients
Psoriasis is a chronic systemic inflammatory disease mediated by the immune system. Interleukin-23 (IL-23) plays a key role in its pathogenesis by amplifying inflammation, triggering atherogenic dyslipidemia and insulin resistance, and thereby increasing cardiovascular and cerebrovascular risk. This study aimed to evaluate the effect of the IL-23 inhibitors risankizumab and guselkumab, used in psoriasis treatment, on cardiovascular and cerebrovascular risk through the plasma atherogenic index (PAI) and triglyceride-glucose (TyG) index. This retrospective study included 110 patients diagnosed with psoriasis and treated with risankizumab (n = 61) or guselkumab (n = 49). Psoriasis Area and Severity Index (PASI) scores, triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C) levels and fasting blood glucose (FBG) values at baseline and at 6 months of treatment were obtained from patient records. The plasma atherogenic index (PAI) was calculated as log₁。(TG/HDL-C), and the triglyceride-glucose (TyG) index as log₁。(TG × FBG / 2). In both IL-23 inhibitor groups included in the study, PASI scores, PAI, and TyG index values showed a significant decrease from baseline at the 6th month of treatment (p < 0.05). However, there was no significant difference in the reduction of index levels between the groups (p > 0.05). IL-23 inhibitors can reduce atherogenic dyslipidemia and insulin resistance alongside dermatological improvement in the treatment of psoriasis. This suggests a potential role for these agents in reducing the risk of cardiovascular and cerebrovascular disease. However, large-scale, long-term studies are needed to confirm these beneficial effects.
- 2 July 2024
- Published by Taylor & Francis in Cutaneous and Ocular Toxicology
- Vol. 43 (3) , 182-189
The relationship between TNF-α, IL-1, IL-12, IL-17, IL-23, IL-36 expression and treatment response in psoriasis histopathologically and immunohistochemically
There is no marker that can predict whether there is resistance to treatment in patients with psoriasis. In this study, we investigated the relationship between the staining rates of TNF-α, IL-1, IL-12, IL-17, IL-23, and IL-36 markers immunohistochemically from cutaneous biopsy and the treatment success. The patients who were followed up in the dermatology clinic with the diagnosis of plaque-type psoriasis vulgaris and received biological treatment and previously had cutaneous biopsy were included in the study. The cutaneous biopsies of the cases that met the conditions were re-sectioned and subjected to immunohistochemical examination for TNF-α, IL-1, IL-12, IL-17, IL-23, and IL-36. Comparing the staining scores with psoriasis area severity index (PASI); A statistically significant positive correlation was found between PASI and TNF-α staining score(p = 0.034). A statistically significant positive correlation was found between PASI and IL-17 staining score(p = 0.004).When the staining scores and PASI response rates of psoriasis treatment were evaluated in terms of correlation; there was a positive correlation between TNF-α, IL-17, and IL-23 immunohistochemical staining rates and PASI response rates. In line with the data obtained from our study, we think that making immunohistochemical scoring before the biological treatment decision in psoriasis patients will be beneficial in treatment selection. In this respect, our study may open a new era in the selection of biological treatments for psoriasis.
- 2 July 2024
- Published by Taylor & Francis in Cutaneous and Ocular Toxicology
- Vol. 43 (3) , 182-189
The relationship between TNF-α, IL-1, IL-12, IL-17, IL-23, IL-36 expression and treatment response in psoriasis histopathologically and immunohistochemically
There is no marker that can predict whether there is resistance to treatment in patients with psoriasis. In this study, we investigated the relationship between the staining rates of TNF-α, IL-1, IL-12, IL-17, IL-23, and IL-36 markers immunohistochemically from cutaneous biopsy and the treatment success. The patients who were followed up in the dermatology clinic with the diagnosis of plaque-type psoriasis vulgaris and received biological treatment and previously had cutaneous biopsy were included in the study. The cutaneous biopsies of the cases that met the conditions were re-sectioned and subjected to immunohistochemical examination for TNF-α, IL-1, IL-12, IL-17, IL-23, and IL-36. Comparing the staining scores with psoriasis area severity index (PASI); A statistically significant positive correlation was found between PASI and TNF-α staining score(p = 0.034). A statistically significant positive correlation was found between PASI and IL-17 staining score(p = 0.004).When the staining scores and PASI response rates of psoriasis treatment were evaluated in terms of correlation; there was a positive correlation between TNF-α, IL-17, and IL-23 immunohistochemical staining rates and PASI response rates. In line with the data obtained from our study, we think that making immunohistochemical scoring before the biological treatment decision in psoriasis patients will be beneficial in treatment selection. In this respect, our study may open a new era in the selection of biological treatments for psoriasis.
- 12 June 2024
- Published by Wiley in International Journal of Dermatology
- Vol. 63 (10) , 1467-1468
Intralesional hyaluronidase as a treatment for fibrosis in hidradenitis suppurativa: a case report
- 12 June 2024
- Published by Wiley in International Journal of Dermatology
- Vol. 63 (10) , 1467-1468
Intralesional hyaluronidase as a treatment for fibrosis in hidradenitis suppurativa: a case report
- 5 January 2024
- Published by Caleo in Rheumatology Quarterly
- Vol. 1 (4) , 130-139
SKIN MANIFESTATIONS OF RHEUMATOLOGICAL DISEASES
Rheumatic diseases have very heterogeneous manifestations and diagnostic criteria. Rheumatic diseases have a wide range of involvement, including systemic (joints and internal organs), as well as skin, mucosa, hair, and nails. Some of these symptoms can cause severe comorbidities and significantly impair the quality of life. Skin findings are critical for early recognition or reinforcing the diagnosis of rheumatic diseases. At the same time, some skin lesions have particular importance as they may be the first and/or most serious comorbid symptom of the disease. Although most of these findings are not specific for rheumatic diseases (such as facial telangiectasia in scleroderma or nonscarring alopecia seen in systemic lupus) some findings may be disease-specific (e.g. discoid lesions in discoid lupus, malar rash in systemic lupus, and Gottron papules in dermatomyositis). Thanks to the contributions of dermatology, the skin findings of rheumatic diseases have become clearer in recent years, thus enabling the classification, phenotyping, and early treatment of rheumatic diseases. Considering all these, each dermatological finding should be taken into consideration and evaluated on a case basis in terms of suspected condition, diagnosis, treatment, and management of post-treatment comorbidities. In conclusion, both rheumatologists and dermatologists have a great responsibility in detailed anamnesis and dermatological examination for detecting the condition, classifying and phenotyping as when necessary, and developing early treatment options.
- 5 January 2024
- Published by Caleo in Rheumatology Quarterly
- Vol. 1 (4) , 130-139
SKIN MANIFESTATIONS OF RHEUMATOLOGICAL DISEASES
Rheumatic diseases have very heterogeneous manifestations and diagnostic criteria. Rheumatic diseases have a wide range of involvement, including systemic (joints and internal organs), as well as skin, mucosa, hair, and nails. Some of these symptoms can cause severe comorbidities and significantly impair the quality of life. Skin findings are critical for early recognition or reinforcing the diagnosis of rheumatic diseases. At the same time, some skin lesions have particular importance as they may be the first and/or most serious comorbid symptom of the disease. Although most of these findings are not specific for rheumatic diseases (such as facial telangiectasia in scleroderma or nonscarring alopecia seen in systemic lupus) some findings may be disease-specific (e.g. discoid lesions in discoid lupus, malar rash in systemic lupus, and Gottron papules in dermatomyositis). Thanks to the contributions of dermatology, the skin findings of rheumatic diseases have become clearer in recent years, thus enabling the classification, phenotyping, and early treatment of rheumatic diseases. Considering all these, each dermatological finding should be taken into consideration and evaluated on a case basis in terms of suspected condition, diagnosis, treatment, and management of post-treatment comorbidities. In conclusion, both rheumatologists and dermatologists have a great responsibility in detailed anamnesis and dermatological examination for detecting the condition, classifying and phenotyping as when necessary, and developing early treatment options.